Switching to sirolimus vs continuing calcineurin inhibitors for the prevention of rejection in renal transplant recipients

Trial Profile

Switching to sirolimus vs continuing calcineurin inhibitors for the prevention of rejection in renal transplant recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Sirolimus (Primary) ; Calcineurin inhibitors
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top